NASDAQ:ANIK
Anika Therapeutics Inc. Stock News
$25.54
+0.180 (+0.710%)
At Close: Mar 27, 2024
Anika Therapeutics Non-GAAP EPS of -$0.23 misses by $0.02, revenue of $35.82M beats by $3.77M
09:28pm, Tuesday, 08'th Mar 2022 Seeking Alpha
Anika Therapeutics press release (ANIK): Q4 Non-GAAP EPS of -$0.23 misses by $0.02.Revenue of $35.82M (+9.6% Y/Y) beats by $3.77M.
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
01:00pm, Tuesday, 08'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates
03:05pm, Monday, 07'th Mar 2022 Zacks Investment Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Beat Estimates
02:35pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.02% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates
11:50pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight
06:00pm, Wednesday, 16'th Feb 2022 Benzinga
New York, USA, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Global Orthobiologics Market is Anticipated to Grow at a CAGR of 4.44% During the Forecast Period (2021-26) | DelveInsight As per DelveInsight analysis, a growing geriatric population at risk of developing various bone degenerative disorders, an increase in traumatic injuries such as car accidents, sports injuries, and others are expected to boost the Orthobiologics market growth. Furthermore rising investments in R&D and collaborations by key manufacturers, as well as an increase in various orthobiologic product approvals will also drive the market. DelveInsight''s Orthobiologics Market Insights and Forecast report provides the current and forecast Orthobiologics market, upcoming developments in the medical devices, individual market shares, challenges, drivers, barriers, market growth trends, and key players in the Orthobiologics market. Some of the Key Highlights from the Orthobiologics Market Report According to DelveInsight analysis, North America is expected to dominate the overall Orthobiologics Market during the forecasted period.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11:50pm, Friday, 11'th Feb 2022 GlobeNewswire Inc.
BEDFORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on February 1,
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
09:01pm, Tuesday, 08'th Feb 2022 GlobeNewswire Inc.
BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company pla
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
09:01pm, Tuesday, 08'th Feb 2022 GlobeNewswire
BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its fourth quarter and year-end 2021 financial results after the close of the market on Tuesday, March 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.
Anika to Issue Fourth Quarter and Year-End 2021 Financial Results on Tuesday, March 8, 2022
04:01pm, Tuesday, 08'th Feb 2022
BEDFORD, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans
Facial Rejuvenation Market to See Booming Growth 2021-2028 | Merz Pharma, Anika Therapeutics, Inc., Lumenis
07:32am, Wednesday, 15'th Dec 2021 OpenPR
The Facial Rejuvenation market report presents the global Facial Rejuvenation sales and revenue by companies, regions, type and application and forecast to 2026. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 10'th Dec 2021 GlobeNewswire Inc.
BEDFORD, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on December 1,
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:00pm, Friday, 10'th Dec 2021 Intrado Digital Media
BEDFORD, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on December 1, 2021, Anika granted non-statutory stock options covering an aggregate of 1,069 shares of common stock (the Options) and restricted stock units (the RSUs) covering an aggregate of 468 shares of common stock to 1 newly hired non-executive employee. Each grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantees acceptance of employment with Anika as a component of the grantees employment compensation.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Sees Significant Decline in Short Interest
07:16am, Friday, 03'rd Dec 2021 Dakota Financial News
Anika Therapeutics, Inc. (NASDAQ:ANIK) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 756,300 shares, a decline of 29.3% from the October 31st total of 1,070,000 shares. Based on an average daily trading volume, of 72,200 shares, the days-to-cover ratio is currently 10.5 []
State of Alaska Department of Revenue Purchases 570 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)
11:32am, Thursday, 02'nd Dec 2021 Transcript Daily
State of Alaska Department of Revenue grew its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 5.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,524 shares of the biotechnology companys stock after purchasing an additional 570 shares during the []